JP2021176893A5 - - Google Patents

Download PDF

Info

Publication number
JP2021176893A5
JP2021176893A5 JP2021123814A JP2021123814A JP2021176893A5 JP 2021176893 A5 JP2021176893 A5 JP 2021176893A5 JP 2021123814 A JP2021123814 A JP 2021123814A JP 2021123814 A JP2021123814 A JP 2021123814A JP 2021176893 A5 JP2021176893 A5 JP 2021176893A5
Authority
JP
Japan
Prior art keywords
pyridin
trifluoromethyl
amino
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021123814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021176893A (ja
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Priority claimed from JP2019082794A external-priority patent/JP2019142930A/ja
Application filed filed Critical
Publication of JP2021176893A publication Critical patent/JP2021176893A/ja
Publication of JP2021176893A5 publication Critical patent/JP2021176893A5/ja
Pending legal-status Critical Current

Links

JP2021123814A 2013-08-02 2021-07-29 治療活性のある化合物及びその使用方法 Pending JP2021176893A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
US61/861,884 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
CNPCT/CN2013/081170 2013-08-09
US201461939098P 2014-02-12 2014-02-12
US61/939,098 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US61/975,448 2014-04-04
US201462011948P 2014-06-13 2014-06-13
US62/011,948 2014-06-13
JP2019082794A JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019082794A Division JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2021176893A JP2021176893A (ja) 2021-11-11
JP2021176893A5 true JP2021176893A5 (cg-RX-API-DMAC7.html) 2022-02-16

Family

ID=52432592

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016531940A Active JP6742905B2 (ja) 2013-08-02 2014-08-01 治療活性のある化合物及びその使用方法
JP2019082794A Withdrawn JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法
JP2021123814A Pending JP2021176893A (ja) 2013-08-02 2021-07-29 治療活性のある化合物及びその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016531940A Active JP6742905B2 (ja) 2013-08-02 2014-08-01 治療活性のある化合物及びその使用方法
JP2019082794A Withdrawn JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法

Country Status (21)

Country Link
US (6) US9738625B2 (cg-RX-API-DMAC7.html)
EP (3) EP3027193A4 (cg-RX-API-DMAC7.html)
JP (3) JP6742905B2 (cg-RX-API-DMAC7.html)
CN (3) CN105916507A (cg-RX-API-DMAC7.html)
AU (2) AU2014295938B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016002287A2 (cg-RX-API-DMAC7.html)
CA (1) CA2919382A1 (cg-RX-API-DMAC7.html)
CL (2) CL2016000263A1 (cg-RX-API-DMAC7.html)
EA (1) EA030428B1 (cg-RX-API-DMAC7.html)
ES (1) ES2886211T3 (cg-RX-API-DMAC7.html)
IL (2) IL243833A0 (cg-RX-API-DMAC7.html)
MX (2) MX389250B (cg-RX-API-DMAC7.html)
MY (1) MY177994A (cg-RX-API-DMAC7.html)
NI (1) NI201600022A (cg-RX-API-DMAC7.html)
PE (1) PE20160840A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500164B1 (cg-RX-API-DMAC7.html)
SA (1) SA516370523B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201709187TA (cg-RX-API-DMAC7.html)
TW (2) TWI666208B (cg-RX-API-DMAC7.html)
UA (1) UA121021C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015017821A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20180134683A1 (en) * 2015-05-07 2018-05-17 Teligene Ltd. Heterocylcic compounds as idh2 inhibitors
AU2016299092B2 (en) 2015-07-30 2020-08-20 Centaurus Biopharma Co., Ltd. 1, 3, 5-triazine derivative and method of using same
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ, インコーポレイテッド 悪性腫瘍の治療のための併用療法
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
JP6588647B2 (ja) * 2015-10-21 2019-10-09 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドNeuform Pharmaceuticals, Inc. 血液悪性腫瘍を治療するための重水素化合物及びその組成物並びに方法
MA43374A (fr) * 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CA3015753A1 (en) * 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
WO2018026894A1 (en) 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
JP7111725B2 (ja) * 2017-01-22 2022-08-02 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 1,3,5-トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
DE59106971D1 (de) 1990-07-12 1996-01-11 Ciba Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
WO2008131547A1 (en) * 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CA2764785C (en) * 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CA2767008C (en) * 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
SMT201800334T1 (it) * 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Similar Documents

Publication Publication Date Title
JP2016527279A5 (cg-RX-API-DMAC7.html)
Liu et al. Small molecule inhibitors targeting the cancers
JP2021098740A5 (cg-RX-API-DMAC7.html)
Jiang et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
JP2020147571A5 (cg-RX-API-DMAC7.html)
Takahashi et al. High-dose intravenous vitamin C improves quality of life in cancer patients
Guo et al. Biological roles and therapeutic applications of IDH2 mutations in human cancer
Kay et al. Proline metabolism shapes the tumor microenvironment: from collagen deposition to immune evasion
Wang et al. Eicosanoid signaling in carcinogenesis of colorectal cancer
EP3134088B1 (en) Bicylcic pyrazolone compounds and methods of use
JP2022071099A5 (cg-RX-API-DMAC7.html)
Huang et al. Depression accelerates the development of gastric cancer through reactive oxygen species‑activated ABL1
JPWO2017200016A1 (ja) Egfr−tki耐性を獲得した肺癌の治療薬
JP2021524835A5 (cg-RX-API-DMAC7.html)
JP5473937B2 (ja) 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド
Malakar et al. The role of BRAF inhibitors in the management of ameloblastoma: a literature review
Naik et al. Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
Romanidou et al. Bridging cancer biology with the clinic: Comprehending and exploiting IDH gene mutations in gliomas
Wang et al. Nanozymes: a new approach for leukemia therapy
CN111249282A (zh) 癌症疗法
Wu et al. A multicenter retrospective study on the prognosis of stage III unresectable mutant non-small cell lung cancer with tyrosine kinase inhibitors therapy
EP3787620A1 (en) Combinations for treating cancer
Ho et al. Cancer Management by Tyrosine Kinase Inhibitors: Efficacy
WO2021210636A1 (ja) 乳がん治療剤
WO2023138011A1 (zh) 不占用核糖体资源的翻译抑制剂作为抗肿瘤药物